Groundbreaking LLNL and BridgeBio Oncology Therapeutics collaboration announces start of human trials for supercomputing-discovered cancer drug

Credit: Graphic by Amanda Levasseur.

In a milestone for supercomputing-aided drug design, Lawrence Livermore National Laboratory and BridgeBio Oncology Therapeutics today announced clinical trials have begun for a first-in-class medication that targets specific genetic mutations implicated in many types of cancer. The drug discovery work was powered by LLNL supercomputers Ruby (shown), Quartz and Lassen.

« Groundbreaking LLNL and BridgeBio Oncology Therapeutics collaboration announces start of human trials for supercomputing-discovered cancer drug

Credit: Picture by LLNL team.

This image depicts a surface representation of the interaction among the cancer drug candidate, BBO-8520 (yellow), the natural substrate guanosine triphosphate (or GTP, orange) and a KRAS protein (cyan).

« Groundbreaking LLNL and BridgeBio Oncology Therapeutics collaboration announces start of human trials for supercomputing-discovered cancer drug

Expert Pitch

Expert Query

Expert Directory